tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Edema D004487 152 associated lipids
Precancerous Conditions D011230 48 associated lipids
Postoperative Complications D011183 5 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Neoplasm Recurrence, Local D009364 5 associated lipids
Osteonecrosis D010020 5 associated lipids
Hypotension D007022 41 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Hossain MA et al. Immunosuppression in auxiliary partial liver transplantation with FK506 in rats. 1997 Transplant. Proc. pmid:9414861
Miyata Y et al. Phosphorylation of the immunosuppressant FK506-binding protein FKBP52 by casein kinase II: regulation of HSP90-binding activity of FKBP52. 1997 Proc. Natl. Acad. Sci. U.S.A. pmid:9405642
Zucker K et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. 1997 Transpl. Immunol. pmid:9402690
Suzuki J et al. Inhibition of accelerated coronary atherosclerosis with short-term blockade of intercellular adhesion molecule-1 and lymphocyte function-associated antigen-1 in a heterotopic murine model of heart transplantation. 1997 J. Heart Lung Transplant. pmid:9402514
Misao T et al. Efficacy of combining donor-specific presensitization with a simultaneous single injection of tacrolimus on pulmonary allografts. 1997 J. Heart Lung Transplant. pmid:9402508
Wijnen RM and Ericzon BG Update of tacrolimus in pancreas transplantation. 1997 Diabet. Med. pmid:9400914
Mollison KW et al. Discovery of less nephrotoxic FK506 analogs and determining immunophilin dependence of immunosuppressant nephrotoxicity with a novel single-dose rat cisplatin potentiation assay. 1997 J. Pharmacol. Exp. Ther. pmid:9400028
Cox TH et al. Bradycardia associated with intravenous administration of tacrolimus in a liver transplant recipient. 1997 Nov-Dec Pharmacotherapy pmid:9399620
Yamaguchi Y et al. Enhanced expression of cytokine-induced neutrophil chemoattractant in rat hepatic allografts during acute rejection. 1997 Hepatology pmid:9397996
Su Y et al. Thyroid hormone induces apoptosis in primary cell cultures of tadpole intestine: cell type specificity and effects of extracellular matrix. 1997 J. Cell Biol. pmid:9396758
Sabatini DM et al. Neural roles of immunophilins and their ligands. 1997 Mol. Neurobiol. pmid:9396011
Schweda F et al. Tacrolimus treatment for steroid- and cyclosporin-resistant minimal-change nephrotic syndrome. 1997 Nephrol. Dial. Transplant. pmid:9394341
Jiang H et al. Distinct tissue and cellular distribution of two major isoforms of calcineurin. 1997 Mol. Immunol. pmid:9393969
Sokal EM et al. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus. 1997 Transplantation pmid:9392308
Kageyama S et al. Augmentation of natural killer cell activity induced by cytomegalovirus infection in mice treated with FK506. 1997 Acta Virol. pmid:9391652
Nyanguile O et al. A nonnatural transcriptional coactivator. 1997 Proc. Natl. Acad. Sci. U.S.A. pmid:9391036
Huang J and Schreiber SL A yeast genetic system for selecting small molecule inhibitors of protein-protein interactions in nanodroplets. 1997 Proc. Natl. Acad. Sci. U.S.A. pmid:9391035
McElwee KJ et al. Topical FK506: a potent immunotherapy for alopecia areata? Studies using the Dundee experimental bald rat model. 1997 Br. J. Dermatol. pmid:9390322
Thyagarajan GK et al. FK506-induced fulminant leukoencephalopathy after single-lung transplantation. 1997 Ann. Thorac. Surg. pmid:9386723
Okudaira H et al. Control of allergic diseases by regulation of cytokine gene transcription. 1997 Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M pmid:9383912
Chakraborty TK et al. Design and synthesis of a rapamycin-based high affinity binding FKBP12 ligand. 1995 Chem. Biol. pmid:9383417
Pruschy MN et al. Mechanistic studies of a signaling pathway activated by the organic dimerizer FK1012. 1994 Chem. Biol. pmid:9383386
Newell KA et al. Treatment with either anti-CD4 or anti-CD8 monoclonal antibodies blocks alphabeta T cell-mediated rejection of intestinal allografts in mice. 1997 Transplantation pmid:9381541
De Gasperi A and Rohrer RJ Scenario number two: sepsis and multiorgan failure after liver transplantation. 1997 Liver Transpl Surg pmid:9377761
Canzanello VJ et al. Evolution of cardiovascular risk after liver transplantation: a comparison of cyclosporine A and tacrolimus (FK506). 1997 Liver Transpl Surg pmid:9377752
Kuromitsu S et al. 3-(13-Hydroxytridecyl)-1-[13-(3-pyridyl)tridecyl]pyridinium chloride (YM-53792), a novel inhibitor of NF-AT activation. 1997 Biochem. Pharmacol. pmid:9374420
Cetinkale O et al. Involvement of neutrophils in ischemic injury. I. Biochemical and histopathological investigation of the effect of FK506 on dorsal skin flaps in rats. 1997 Ann Plast Surg pmid:9374148
Rudant E et al. Study of the correlation between MEIA and ELISA methods for FK 506 determination in liver transplant recipients. 1997 J Clin Pharm Ther pmid:9373812
Eberlein-König B et al. Modulation of histamine release in vitro by FK506 and interleukin-3 is determined by sequence of incubation. 1997 Arch. Dermatol. Res. pmid:9373722
Kloke O et al. Rapamycin antagonizes interleukin-6 mediated growth arrest and differentiation of myeloblastic M1 cells. 1997 Immunol. Lett. pmid:9373220
Migita K et al. FK506 potentiates steroid-induced T-cell apoptosis. 1997 Transplantation pmid:9371682
Lee CM et al. Outcomes in diabetic patients after simultaneous pancreas-kidney versus kidney alone transplantation. 1997 Transplantation pmid:9371670
Ross DJ et al. FK 506 'rescue' immunosuppression for obliterative bronchiolitis after lung transplantation. 1997 Chest pmid:9367453
Aoyama S et al. [The effect of FK 506, an immunosuppressant, on cerebral infarction volume in focal cerebral ischemia in rats]. 1997 Nippon Ika Daigaku Zasshi pmid:9366145
Takao T et al. [A case of recurrent IgA nephropathy following renal transplantation under tacrolimus (FK506)]. 1997 Hinyokika Kiyo pmid:9365847
Niederstadt C et al. Effect of FK506 on magnesium homeostasis after renal transplantation. 1997 Transplant. Proc. pmid:9365709
Gavlik A et al. Mycophenolate mofetil rescue therapy in liver transplant recipients: an extended follow-up. 1997 Transplant. Proc. pmid:9365633
Xu M et al. Effect of peritransplant FTY720 alone or in combination with posttransplant FK 506 in a rat model of cardiac allotransplantation. 1997 Transplant. Proc. pmid:9365631
Kliem V et al. Long-term results after primary successful FK 506 treatment of steroid- and OKT3-resistant rejection in renal transplant recipients. 1997 Transplant. Proc. pmid:9365627
Demirbas A et al. FK 506 in simultaneous pancreas/kidney transplantation: the University of Miami experience. 1997 Transplant. Proc. pmid:9365608
Platz KP et al. Indications for mycofenolate mofetil therapy after liver transplantation. 1997 Transplant. Proc. pmid:9365601
Platz KP et al. FK 506 and mycofenolate mofetil rescue for acute steroid-resistant and chronic rejection after liver transplantation. 1997 Transplant. Proc. pmid:9365598
Mueller AR et al. Association between hepatitis and rejection: upregulation of cytokines and extracellular matrix parameters. 1997 Transplant. Proc. pmid:9365585
Taylor PJ et al. Improved therapeutic drug monitoring of tacrolimus (FK506) by tandem mass spectrometry. 1997 Clin. Chem. pmid:9365410
Dumont FJ FK506 enhances IL-13 production by T cells activated through CD3/CD28. 1997 Int. Arch. Allergy Immunol. pmid:9363914
Xenos EX et al. The use of tacrolimus as induction and maintenance immunosuppression in renal cadaveric transplant recipients over the age of 60. 1997 Clin Transplant pmid:9361949
Neu AM et al. Evaluation of neurotoxicity in pediatric renal transplant recipients treated with tacrolimus (FK506). 1997 Clin Transplant pmid:9361932
Reyes J et al. Graft-versus-host disease after liver and small bowel transplantation in a child. 1997 Clin Transplant pmid:9361921
Nakai A et al. The immunosuppressant drug FK506 ameliorates secondary mitochondrial dysfunction following transient focal cerebral ischemia in the rat. 1997 Neurobiol. Dis. pmid:9361306
Rinaldi M et al. FK506 effectiveness in reducing acute rejection after heart transplantation: a prospective randomized study. 1997 J. Heart Lung Transplant. pmid:9361242